← Back to Patent Explorer
EP0353692A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

Drug effect-enhancing agent for antitumor drug

Assignee: Nissan Chemical Corp
•
Filing: 1989-07-31
•
Granted: —
•
Expires: 2009-07-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An agent for enhancing the drug effects of an antitumor drug, which comprises a compound of the formula I: wherein Ar¹ is phenyl, pyridyl, furyl or 2,1,3-­benzooxadiazol-4-yl, which may be substituted by one or two substituents selected from the group consisting of NO₂, CF₃, Br, Cl, F, R⁶ (wherein R⁶ is C₁-C₄ alkyl), OH, OR⁶, OCHF₂, COOR⁶, NH₂, NHR⁶, NR⁶R⁷ (wherein R⁷ has the same meaning as R⁶), CONH₂, CONHR⁶, CONR⁶R⁷, COSR⁶, SR⁶, S(O)R⁶, S(O)₂R⁶, SO₃H, SO₃R⁶, SO₂NH₂, SO₂NHR⁶, SO₂NR⁶R⁷, CN and phenyloxy; the nitrogen-containing hetero ring portion represents a 1,4-dihydropyridine ring or a pyridine ring; Z is a group of the formula II: wherein each of R⁴ and R⁵ which may be the same or different is OH, C₁-C₁₂ linear or branched primary or secondary alkyloxy, C₃-C₆ linear or branched unsaturated alkyloxy, C₃-C₆ cycloalkyloxy, C₁-C₆ alkoxy substituted by C₃-C₆ cycloalkyl, OAr² (wherein Ar² is phenyl which may be substituted by halogen, C₁-C₃ alkyl or C₁-C₃ alkoxy), OANR⁶R⁷ (wherein A is C₂-C₆ alkylene which may be substituted by C₁-C₃ alkyl or Ar²), OAN(CH₂Ar²)R⁶, OAOR⁶, OACN, NH₂, NHR⁶, NR⁶R⁷, 1-piperidinyl or 1-­pyrrolidinyl, or R⁴ and R⁵ together form OYO (wherein Y is C₂-C₄ linear saturated or unsaturated alkylene which may be substituted by R⁶, CO₂R⁶, OR⁶ or A), NHYO, R⁶NYO, NHYNH, R⁶NYNH or R⁶NYNR⁷, or Z is CO₂R⁸ (wherein R⁸ has the same meaning as R³ defined hereinafter); R¹ is present only when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and it is R⁶, ANR⁶R⁷, AN(CH₂CH₂)₂O, AOR⁶ or CH₂phenyl; R² is R⁶, Ar², Ar²CH=CH, Ar²CH(OH)CH₂, CHO, CN, CH₂OH, CH₂OR⁶, CH₂CH₂N(CH₂CH₂)₂NR⁶, NH₂, NHR⁶ or NR⁶R⁷; R³ is hydrogen, C₁-C₁₂ linear or branched alkyl, C₃-C₆ linear or branched unsaturated alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkyl substituted by C₃-C₆ cycloalkyl, AOR⁶, AO(CH₂) m Ar² (wherein m is an integer of from 0 to 3), (CH₂) m Ar², ANH₂, ANHR⁶, ANR⁶R⁷, ANR⁶(CH₂) m Ar², AN{(CH₂) m Ar²}{(CH₂) n Ar³} (wherein n has the same meaning as m, and Ar³ has the same meaning as Ar²), 1-benzyl-4-­piperidinyl, 1-benzyl-2-piperidinyl, 2-pyridinylmethyl, 3-pyridinylmethyl, AQ (wherein Q is pyrrolidine or piperidine which may be substituted by (CH₂) m Ar²), 4-R⁶-­ 1-piperazinyl, 4-Ar²-1-piperazinyl, 4-(Ar²)₂CH-1-­piperazinyl or 4-(Ar²)₂CH-1-(1,4-diazacycloheptyl); or a pharmaceutically acceptable salt of the compound.

Inventors

  • 👤 Shin-Ichi Akiyama
  • 👤 Ryozo Sakoda
  • 👤 Kiyotomo Seto
  • 👤 Norimasa Seibutsukagaku Kenkyusho Shudo

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-10-23 19:59
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/495; A61K31/535; A61K31/66; A61K31/665; A61K31/675; C; C07; C07F; C07F9/00; C07F9/02; C07F9/547; C07F9/553; C07F9/576; C07F9/58; C07F9/59

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 363 words
An agent for enhancing the drug effects of an antitumor drug, which comprises a compound of the formula I: wherein Ar¹ is phenyl, pyridyl, furyl or 2,1,3-­benzooxadiazol-4-yl, which may be substituted by one or two substituents selected from the group consisting of NO₂, CF₃, Br, Cl, F, R⁶ (wherein R⁶ is C₁-C₄ alkyl), OH, OR⁶, OCHF₂, COOR⁶, NH₂, NHR⁶, NR⁶R⁷ (wherein R⁷ has the same meaning as R⁶), CONH₂, CONHR⁶, CONR⁶R⁷, COSR⁶, SR⁶, S(O)R⁶, S(O)₂R⁶, SO₃H, SO₃R⁶, SO₂NH₂, SO₂NHR⁶, SO₂NR⁶R⁷, CN and phenyloxy; the nitrogen-containing hetero ring portion represents a 1,4-dihydropyridine ring or a pyridine ring; Z is a group of the formula II: wherein each of R⁴ and R⁵ which may be the same or different is OH, C₁-C₁₂ linear or branched primary or secondary alkyloxy, C₃-C₆ linear or branched unsaturated alkyloxy, C₃-C₆ cycloalkyloxy, C₁-C₆ alkoxy substituted by C₃-C₆ cycloalkyl, OAr² (wherein Ar² is phenyl which may be substituted by halogen, C₁-C₃ alkyl or C₁-C₃ alkoxy), OANR⁶R⁷ (wherein A is C₂-C₆ alkylene which may be substituted by C₁-C₃ alkyl or Ar²), OAN(CH₂Ar²)R⁶, OAOR⁶, OACN, NH₂, NHR⁶, NR⁶R⁷, 1-piperidinyl or 1-­pyrrolidinyl, or R⁴ and R⁵ together form OYO (wherein Y is C₂-C₄ linear saturated or unsaturated alkylene which may be substituted by R⁶, CO₂R⁶, OR⁶ or A), NHYO, R⁶NYO, NHYNH, R⁶NYNH or R⁶NYNR⁷, or Z is CO₂R⁸ (wherein R⁸ has the same meaning as R³ defined hereinafter); R¹ is present only when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and it is R⁶, ANR⁶R⁷, AN(CH₂CH₂)₂O, AOR⁶ or CH₂phenyl; R² is R⁶, Ar², Ar²CH=CH, Ar²CH(OH)CH₂, CHO, CN, CH₂OH, CH₂OR⁶, CH₂CH₂N(CH₂CH₂)₂NR⁶, NH₂, NHR⁶ or NR⁶R⁷; R³ is hydrogen, C₁-C₁₂ linear or branched alkyl, C₃-C₆ linear or branched unsaturated alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkyl substituted by C₃-C₆ cycloalkyl, AOR⁶, AO(CH₂) m Ar² (wherein m is an integer of from 0 to 3), (CH₂) m Ar², ANH₂, ANHR⁶, ANR⁶R⁷, ANR⁶(CH₂) m Ar², AN{(CH₂) m Ar²}{(CH₂) n Ar³} (wherein n has the same meaning as m, and Ar³ has the same meaning as Ar²), 1-benzyl-4-­piperidinyl, 1-benzyl-2-piperidinyl, 2-pyridinylmethyl, 3-pyridinylmethyl, AQ (wherein Q is pyrrolidine or piperidine which may be substituted by (CH₂) m Ar²), 4-R⁶-­ 1-piperazinyl, 4-Ar²-1-piperazinyl, 4-(Ar²)₂CH-1-­piperazinyl or 4-(Ar²)₂CH-1-(1,4-diazacycloheptyl); or a pharmaceutically acceptable salt of the compound.
Claim 2
Dependent Claim 363 words
An agent for enhancing the drug effects of an antitumor drug, which comprises a compound of the formula I: wherein Ar¹ is phenyl, pyridyl, furyl or 2,1,3-­benzooxadiazol-4-yl, which may be substituted by one or two substituents selected from the group consisting of NO₂, CF₃, Br, Cl, F, R⁶ (wherein R⁶ is C₁-C₄ alkyl), OH, OR⁶, OCHF₂, COOR⁶, NH₂, NHR⁶, NR⁶R⁷ (wherein R⁷ has the same meaning as R⁶), CONH₂, CONHR⁶, CONR⁶R⁷, COSR⁶, SR⁶, S(O)R⁶, S(O)₂R⁶, SO₃H, SO₃R⁶, SO₂NH₂, SO₂NHR⁶, SO₂NR⁶R⁷, CN and phenyloxy; the nitrogen-containing hetero ring portion represents a 1,4-dihydropyridine ring or a pyridine ring; Z is a group of the formula II: wherein each of R⁴ and R⁵ which may be the same or different is OH, C₁-C₁₂ linear or branched primary or secondary alkyloxy, C₃-C₆ linear or branched unsaturated alkyloxy, C₃-C₆ cycloalkyloxy, C₁-C₆ alkoxy substituted by C₃-C₆ cycloalkyl, OAr² (wherein Ar² is phenyl which may be substituted by halogen, C₁-C₃ alkyl or C₁-C₃ alkoxy), OANR⁶R⁷ (wherein A is C₂-C₆ alkylene which may be substituted by C₁-C₃ alkyl or Ar²), OAN(CH₂Ar²)R⁶, OAOR⁶, OACN, NH₂, NHR⁶, NR⁶R⁷, 1-piperidinyl or 1-­pyrrolidinyl, or R⁴ and R⁵ together form OYO (wherein Y is C₂-C₄ linear saturated or unsaturated alkylene which may be substituted by R⁶, CO₂R⁶, OR⁶ or A), NHYO, R⁶NYO, NHYNH, R⁶NYNH or R⁶NYNR⁷, or Z is CO₂R⁸ (wherein R⁸ has the same meaning as R³ defined hereinafter); R¹ is present only when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and it is R⁶, ANR⁶R⁷, AN(CH₂CH₂)₂O, AOR⁶ or CH₂phenyl; R² is R⁶, Ar², Ar²CH=CH, Ar²CH(OH)CH₂, CHO, CN, CH₂OH, CH₂OR⁶, CH₂CH₂N(CH₂CH₂)₂NR⁶, NH₂, NHR⁶ or NR⁶R⁷; R³ is hydrogen, C₁-C₁₂ linear or branched alkyl, C₃-C₆ linear or branched unsaturated alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkyl substituted by C₃-C₆ cycloalkyl, AOR⁶, AO(CH₂) m Ar² (wherein m is an integer of from 0 to 3), (CH₂) m Ar², ANH₂, ANHR⁶, ANR⁶R⁷, ANR⁶(CH₂) m Ar², AN{(CH₂) m Ar²}{(CH₂) n Ar³} (wherein n has the same meaning as m, and Ar³ has the same meaning as Ar²), 1-benzyl-4-­piperidinyl, 1-benzyl-2-piperidinyl, 2-pyridinylmethyl, 3-pyridinylmethyl, AQ (wherein Q is pyrrolidine or piperidine which may be substituted by (CH₂) m Ar²), 4-R⁶-­ 1-piperazinyl, 4-Ar²-1-piperazinyl, 4-(Ar²)₂CH-1-­piperazinyl or 4-(Ar²)₂CH-1-(1,4-diazacycloheptyl); or a pharmaceutically acceptable salt of the compound.
Claim 3
Dependent Claim 36 words
The agent according to Claim 1, wherein any one of substituents R¹, R², R³, R⁴ and R⁵ in the compound of the formula I contains at least one basic nitrogen atom capable of forming a salt.
Claim 4
Dependent Claim 22 words
The agent according to Claim 2, wherein the nitrogen-­containing hetero ring in the compound of the formula I is a pyridine ring.
Claim 5
Dependent Claim 15 words
The agent according to Claim 3, wherein Z is the group of the formula II.
Claim 6
Dependent Claim 22 words
An antitumor composition comprising a compound of the formula I as defined in Claim 1 and an antitumor drug, as active ingredients.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag